{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:54:40Z","timestamp":1785837280110,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"DOI":"10.7759\/cureus.82957","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:45:38Z","timestamp":1745563538000},"source":"Crossref","is-referenced-by-count":1,"title":["The Effectiveness of Hypomethylating Agents in Elderly Patients With Acute Myeloid Leukemia: Insights From a Single-Center Experience"],"prefix":"10.7759","author":[{"given":"Cristina","family":"Negotei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliana","family":"Mitu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Stanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Angelescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai-Emilian","family":"Lapadat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta M","family":"Berbec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Colita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092342","article-title":"Azacitidine vs. decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA Registry","volume":"14","author":"Labrador J","year":"2022","unstructured":"Labrador J, Mart\u00ednez-Cuadr\u00f3n D, de la Fuente A, et al.. Azacitidine vs. decitabine in unfit newly diagnosed acute myeloid leukemia patients: results from the PETHEMA Registry. Cancers (Basel). 2022, 14:10.3390\/cancers14092342","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206429","article-title":"A review of FLT3 kinase inhibitors in AML","volume":"12","author":"Negotei C","year":"2023","unstructured":"Negotei C, Colita A, Mitu I, et al.. A review of FLT3 kinase inhibitors in AML. J Clin Med. 2023, 12:10.3390\/jcm12206429","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16040074","article-title":"Incorporation of a comorbidity index in treatment decisions for elderly AML patients can lead to better disease management-a single-center experience","volume":"16","author":"Negotei C","year":"2024","unstructured":"Negotei C, Mitu I, Angelescu S, et al.. Incorporation of a comorbidity index in treatment decisions for elderly AML patients can lead to better disease management-a single-center experience. Hematol Rep. 2024, 16:781-94. 10.3390\/hematolrep16040074","journal-title":"Hematol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study","volume":"96","author":"Pollyea DA","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, et al.. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021, 96:208-17. 10.1002\/ajh.26039","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.858202","article-title":"Outcomes of newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: a propensity score-adjusted cohort study","volume":"12","author":"Mustafa Ali MK","year":"2022","unstructured":"Mustafa Ali MK, Corley EM, Alharthy H, et al.. Outcomes of newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: a propensity score-adjusted cohort study. Front Oncol. 2022, 12:858202. 10.3389\/fonc.2022.858202","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225677","article-title":"Use of azacitidine or decitabine for the up-front setting in acute myeloid leukaemia: a systematic review and meta-analysis","volume":"13","author":"Saiz-Rodr\u00edguez M","year":"2021","unstructured":"Saiz-Rodr\u00edguez M, Labrador J, Cuevas B, et al.. Use of azacitidine or decitabine for the up-front setting in acute myeloid leukaemia: a systematic review and meta-analysis. Cancers (Basel). 2021, 13:10.3390\/cancers13225677","journal-title":"Cancers (Basel)"},{"key":"ref7","article-title":"Particular clinical and therapeutical aspects in acute myeloid leukemia in elderly patients","volume":"6","author":"Colita A","year":"2011","unstructured":"Colita A, Colita A, Berbec NM, Angelescu S, Lupu AR. Particular clinical and therapeutical aspects in acute myeloid leukemia in elderly patients. Maedica (Bucur). 2011, 6:287-9.","journal-title":"Maedica (Bucur)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2016.009","article-title":"Treatment with low-dose cytarabine in elderly patients (age 70 years or older) with acute myeloid leukemia: a single institution experience","volume":"8","author":"Heiblig M","year":"2016","unstructured":"Heiblig M, Elhamri M, Tigaud I, et al.. Treatment with low-dose cytarabine in elderly patients (age 70 years or older) with acute myeloid leukemia: a single institution experience. Mediterr J Hematol Infect Dis. 2016, 8:e2016009. 10.4084\/MJHID.2016.009","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.701690","article-title":"Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis","volume":"12","author":"Ma J","year":"2021","unstructured":"Ma J, Ge Z. Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis. Front Pharmacol. 2021, 12:701690. 10.3389\/fphar.2021.701690","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01948-8","article-title":"The clinical value of decitabine monotherapy in patients with acute myeloid leukemia","volume":"39","author":"Santini V","year":"2022","unstructured":"Santini V, L\u00fcbbert M, Wierzbowska A, Ossenkoppele GJ. The clinical value of decitabine monotherapy in patients with acute myeloid leukemia. Adv Ther. 2022, 39:1474-88. 10.1007\/s12325-021-01948-8","journal-title":"Adv Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2185603","article-title":"Assessing eligibility for treatment in acute myeloid leukemia in 2023","volume":"16","author":"Venditti A","year":"2023","unstructured":"Venditti A, Cairoli R, Caira M, et al.. Assessing eligibility for treatment in acute myeloid leukemia in 2023. Expert Rev Hematol. 2023, 16:181-90. 10.1080\/17474086.2023.2185603","journal-title":"Expert Rev Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2023.2212536","article-title":"Treatment of acute myeloid leukaemia in older patients - scope of intensive therapy? - A retrospective analysis","volume":"28","author":"Mayer K","year":"2023","unstructured":"Mayer K, Serries M, Hahn-Ast C, Bisht S, Brossart P, Feldmann G. Treatment of acute myeloid leukaemia in older patients - scope of intensive therapy? - A retrospective analysis. Hematology. 2023, 28:2212536. 10.1080\/16078454.2023.2212536","journal-title":"Hematology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13293","article-title":"Acute myeloid leukaemia in patients we judge as being older and\/or unfit","volume":"290","author":"Lazarevic VL","year":"2021","unstructured":"Lazarevic VL. Acute myeloid leukaemia in patients we judge as being older and\/or unfit. J Intern Med. 2021, 290:279-93. 10.1111\/joim.13293","journal-title":"J Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller A","year":"2024","unstructured":"Bataller A, Bazinet A, DiNardo CD, et al.. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024, 8:927-35. 10.1182\/bloodadvances.2023011757","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3274","article-title":"A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia","volume":"42","author":"Manda S","year":"2024","unstructured":"Manda S, Anz BM 3rd, Benton C, et al.. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematol Oncol. 2024, 42:e3274. 10.1002\/hon.3274","journal-title":"Hematol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0365","article-title":"FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia","volume":"25","author":"Norsworthy KJ","year":"2019","unstructured":"Norsworthy KJ, By K, Subramaniam S, et al.. FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2019, 25:6021-5. 10.1158\/1078-0432.CCR-19-0365","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner H","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al.. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017, 129:424-47. 10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian H","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, et al.. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021, 11:41. 10.1038\/s41408-021-00425-3","journal-title":"Blood Cancer J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret H","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, et al.. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015, 126:291-9. 10.1182\/blood-2015-01-621664","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al.. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020, 383:617-29. 10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184618","article-title":"Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies","volume":"15","author":"Ucciero A","year":"2023","unstructured":"Ucciero A, Pagnoni F, Scotti L, et al.. Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies. Cancers (Basel). 2023, 15:10.3390\/cancers15184618","journal-title":"Cancers (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00672-y","article-title":"To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia","volume":"12","author":"Gangat N","year":"2022","unstructured":"Gangat N, Tefferi A. To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia. Blood Cancer J. 2022, 12:75. 10.1038\/s41408-022-00672-y","journal-title":"Blood Cancer J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357346-the-effectiveness-of-hypomethylating-agents-in-elderly-patients-with-acute-myeloid-leukemia-insights-from-a-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:45:38Z","timestamp":1745563538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357346-the-effectiveness-of-hypomethylating-agents-in-elderly-patients-with-acute-myeloid-leukemia-insights-from-a-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.82957","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}